Monday, 26 Aug 2019

You are here

Improved Survival with Renal Transplant in SLE

The Annals of Internal Medicine has published a cohort study of lupus nephritis (LN) patients with end-stage renal disease (ESRD), showing that renal transplantation is associated with improved survival benefit, with a reduction in death from cardiovascular (CV) disease and infection.

A nationwide cohort study analyzed the national database of nearly all patients with ESRD (United States Renal Data System) and looked at those with incident LN-ESRD who were waitlisted for a renal transplant.

Of the 9659 patients with wait-listed LN-ESRD, 5738 (59%) had a renal transplant.

Transplantation was associated with a reduction in:

  • All-cause mortality (adjusted HR, 0.30 [95% CI, 0.27 to 0.33])
  • CV death (adj. HR 0.26 [CI, 0.23 to 0.30]
  • Death from coronary heart disease 0.30 (CI, 0.19 to 0.48) for ,
  • Death from infection 0.41 (CI, 0.32 to 0.52)
  • Death from Sepsis (aHR 0.41 (CI, 0.31 to 0.53) 

Renal transplant was associated with a significant survival benefit and highlights the benefit of timely referral for LN-ESRD patients needing transplantation.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Sjogren's Syndrome at Risk for Psychiatric Disorders

A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS). 

Abatacept Disappoints in Systemic Sclerosis

A 12‐month, Phase 2 trial has shown that subcutaneous abatacept was well tolerated in patients with diffuse cutaneous systemic sclerosis (dcSSc), but failed to significantly change the skin outcomes as measured by the change in modified Rodnan skin score (mRSS)

FDA AAC Splits Vote in Favor of Nintedanib for Scleroderma Interstitial Lung Disease

The FDA convened Arthritis Advisory Committee to consider nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) and voted 10-7 in favor of approving the drug for this new indication.